默沙东2022年四季度营收（亿美元）：138.3，预期：136.67，前值：135.21。
四季度净利润（亿美元）：30.17，预期：31.39，前值：37.58。
四季度EPS：$1.18，预期：$1.235，前值：$1.48。
四季度调整后每股盈利1.62美元，市场预期1.54美元。
四季度调整后毛利率75.7%，市场预期75%。
四季度（用于癌症免疫疗法的）帕博利珠单抗Keytruda销售额54.5亿美元，市场预期54.5亿美元。
业绩预期
预计2023年营收572亿至587亿美元，市场预期580.7亿美元。
预计2023年调整后每股盈利6.8至6.95美元。
默沙东盘前走弱，截至发稿跌近3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments